Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyoscine butyl bromide for shortening the first stage of labour in nulliparous women
PACTR202402717378543Phase 2Completed
- Sponsor
- Dr. Yibala Edimek
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of hyoscine butylbromide (2 arms), sponsored by Dr. Yibala Edimek. Primary endpoint: Duration of the first stage of labour. Started Oct 2022; status: completed.
02
Drugs
hyoscine butylbromide
Beyond the preview
Go deeper on PACTR202402717378543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202402717378543.